Lp(a)HORIZON (H-46928)

Lp(a)HORIZON is an outcome study to determine whether treatment with an investigational drug reduces risk for major cardiovascular events in patients with cardiovascular disease and elevated lipoprotein(a) level. Participants will be randomized to receive monthly subcutaneous injections of drug or placebo for approximately four years. Eligibility requirements include previous myocardial infarction or ischemic stroke (at least three months before but no more than 10 years before screening) or current symptomatic peripheral artery disease, and lipoprotein(a) 70 mg/dL or higher at screening.